AR080096A1 - Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib - Google Patents
Tratamiento combinado de cancer de pancreas con gemcitabina y masitinibInfo
- Publication number
- AR080096A1 AR080096A1 ARP110100330A ARP110100330A AR080096A1 AR 080096 A1 AR080096 A1 AR 080096A1 AR P110100330 A ARP110100330 A AR P110100330A AR P110100330 A ARP110100330 A AR P110100330A AR 080096 A1 AR080096 A1 AR 080096A1
- Authority
- AR
- Argentina
- Prior art keywords
- masitinib
- gemcitabine
- treatment
- day
- types
- Prior art date
Links
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 9
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 8
- 229960004655 masitinib Drugs 0.000 title abstract 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 6
- 229960005277 gemcitabine Drugs 0.000 abstract 6
- 201000002528 pancreatic cancer Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000009956 adenocarcinoma Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000000496 pancreas Anatomy 0.000 abstract 2
- 230000003442 weekly effect Effects 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Tratamiento combinado de tipos de cáncer de páncreas, especialmente en pacientes con metástasis y en pacientes cuyo cáncer está desarrollando resistencia al tratamiento de primera línea con gemcitabina, que comprende la administracion de masitinib y gemcitabina, ambos en regímenes de dosificacion adecuados, que permiten la resensibilizacion de las células cancerosas ante la gemcitabina. Reivindicacion 1: Uso combinado de masitinib -o una sal farmacéuticamente aceptable de este- y gemcitabina -o una sal farmacéuticamente aceptable de esta- para la preparacion de un medicamento para el tratamiento de tipos de cáncer de páncreas, tales como el adenocarcinoma de páncreas, en pacientes humanos, caracterizado porque masitinib debe administrarse diariamente, en una dosis inicial comprendida entre 6 mg/kg/día y 12 mg/kg/día, y la gemcitabina debe administrarse en una dosis semanal de 1000 +- 250 mg/m2 de área superficial del paciente, durante hasta siete semanas consecutivas como inicio, seguido por una semana sin tratamiento, seguido por ciclos de dosificacion semanal de 1000 +- 250 mg/m2 durante 3 semanas, cada 28 días. Reivindicacion 3: El uso o el método de acuerdo con la reivindicacion 1 o 2, caracterizados porque masitinib es mesilato de masitinib. Reivindicacion 5: El uso o el método de acuerdo con una de las reivindicaciones 1 a 4, caracterizados porque la dosis de masitinib se aumenta hasta alcanzar 15 mg/kg/día. Reivindicacion 7: Un kit que comprende masitinib y gencitabina, o las sales de estos, conjuntamente con instrucciones para usar tanto masitinib como gemcitabina para el tratamiento de tipos de cáncer de páncreas, tales como el adenocarcinoma de páncreas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30017810P | 2010-02-01 | 2010-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080096A1 true AR080096A1 (es) | 2012-03-14 |
Family
ID=43794999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100330A AR080096A1 (es) | 2010-02-01 | 2011-02-01 | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120309706A1 (es) |
| AR (1) | AR080096A1 (es) |
| TW (1) | TW201130830A (es) |
| WO (1) | WO2011092338A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037368B1 (ru) * | 2012-10-04 | 2021-03-19 | Аб Сьянс | Способ лечения рака поджелудочной железы у пациента, страдающего от связанной с болезнью интенсивной боли, и применение набора, содержащего маситиниб или его фармацевтически приемлемую соль и гемцитаниб, для лечения рака поджелудочной железы |
| EP2922572A1 (en) * | 2012-11-23 | 2015-09-30 | AB Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| WO2014113406A1 (en) * | 2013-01-15 | 2014-07-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating pancreatic cancer |
| GB201314485D0 (en) * | 2013-08-13 | 2013-09-25 | Electrophoretics Ltd | Materials and methods relating to pancreatic cancer |
| US20160244845A1 (en) * | 2013-10-04 | 2016-08-25 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| WO2015058034A1 (en) * | 2013-10-18 | 2015-04-23 | The Regents Of The University Of Colorado, A Body Corporate | Use of tyrosine kinase inhibitor in cancer treatment |
| US20160128999A1 (en) * | 2014-11-12 | 2016-05-12 | Ab Science | Masitinib for treating hepatic cancer |
| US20180235936A1 (en) * | 2017-02-17 | 2018-08-23 | University Of Notre Dame Du Lac | Cancer treatment methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014903A1 (en) | 2002-08-02 | 2004-02-19 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| WO2008084103A1 (en) * | 2007-01-12 | 2008-07-17 | Ab Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
| PL2366703T3 (pl) | 2007-02-13 | 2015-02-27 | Ab Science | Postać polimorficzna pochodnej 2-amino-(nitroarylo)-tiazolu |
-
2011
- 2011-02-01 US US13/576,363 patent/US20120309706A1/en not_active Abandoned
- 2011-02-01 WO PCT/EP2011/051348 patent/WO2011092338A1/en not_active Ceased
- 2011-02-01 AR ARP110100330A patent/AR080096A1/es unknown
- 2011-02-01 TW TW100104045A patent/TW201130830A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011092338A1 (en) | 2011-08-04 |
| US20120309706A1 (en) | 2012-12-06 |
| TW201130830A (en) | 2011-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |